Killian Meara

Investigators conducted a study to assess the impact of combined diet and exercise interventions in patients with type 2 diabetes.

A discussion with Madison Irwin, PharmD, BCPS, clinical pharmacist specialist in palliative care at University of Michigan Health and clinical assistant professor at the University of Michigan College of Pharmacy.

A conversation with Rakesh Jain, MD, MPH, clinical professor in the Department of Psychiatry at Texas Tech University School of Medicine.

Research presented at ACCP 2024 found that addiction medicine consult services could help increase medication for opioid use disorder initiation.

Check out important updates from the FDA for the week of October 7.

A study published in Arteriosclerosis, Thrombosis, and Vascular Biology found the risk of major adverse cardiac events was higher in patients hospitalized with COVID-19.

Guselkumab is currently approved by the FDA to treat adults with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, and adults with moderately to severely active ulcerative colitis.

This year’s annual meeting of the American College of Chest Physicians featured more than 300 educational sessions, insights from over 600 faculty members, and 29.5 hours of CE credits.

Research presented at CHEST 2024 examined outcomes of COVID-19 on patients with alcoholic liver disease, cirrhosis, and non-alcohol steatohepatitis.

Emily Endres, BSPS, vice president of pharmacy at PQS by Innovaccer, provides insights into the industry’s next phase.

Research Presented at CHEST 2024 reported on how mepolizumab can improve asthma control, and reduce exacerbations of concurrent asthma and COPD.

The Healgen Rapid Check COVID-19/Flu A&B Antigen Test is the first at-home test to be granted marketing authorization using a traditional premarket review pathway.

Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and COPD.

Research being presented at CHEST 2024 analyzed morbidity and outcomes of children infected with influenza, COVID-19 or both.

A roundtable session discussed the real-world implications of applying DIR fees at the point of sale rather than through retroactive clawback.

The company will be presenting the full BATURA study data as a late-breaker oral presentation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.

Although there has recently been an effort to improve pediatric pain treatment, it is still often underestimated and not adequately managed.

Cologuard Plus is approved for adults aged 45 years and older who are at average risk for the disease.

Check out important updates from the FDA for the week of September 30.

Researchers suggest that vaccine champion programs could be a promising avenue to increasing immunization rates.

This year’s meeting will take place from October 6 to 9 in Boston, Massachusetts.

Several posters presented at the Heart Failure Society of America 2024 Annual Meeting looked into the landscape of guideline-directed medical therapy.

The once-daily, extended release, oral suspension medication was approved by the FDA in May 2024.

Two posters presented at the Heart Failure Society of America 2024 Annual Meeting looked deeper into the topic of statin use in heart transplant recipients.

Angiotensin neprilysin inhibitors have shown to reduce the risk of death and hospitalization due to heat failure, but high prescription costs are a current barrier.

Sara T. Thomason discuses the impact of stigma on pharmacists who are dealing with substance use disorder, the importance of mental health care, and how schools support pharmacy students dealing with addiction.

Catch up on important pain management news from the month of September 2024.

Check out these important FDA updates from the month of September 2024.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the IL4 and IL13 pathways.